Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2015 by European Organisation for Research and Treatment of Cancer - EORTC.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC Identifier:
First received: May 14, 2004
Last updated: February 9, 2015
Last verified: February 2015

RATIONALE: Lonafarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving lonafarnib together with temozolomide may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of lonafarnib when given together with temozolomide in treating patients with recurrent primary supratentorial glioma.

Condition Intervention Phase
Brain and Central Nervous System Tumors
Drug: lonafarnib
Drug: temozolomide
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas

Resource links provided by NLM:

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Dose-limiting toxicity and maximum tolerated dose of lonafarnib determined by CTCAE v3.0

Secondary Outcome Measures:
  • Response (complete [CR] or partial response [PR]) measured by McDonald's criteria at least 4 weeks after first documented response and every 8 weeks until disease progression or until start of another treatment

Estimated Enrollment: 30
Study Start Date: March 2004
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the maximum tolerated dose and dose-limiting toxicity of lonafarnib when administered with temozolomide in patients with recurrent primary supratentorial gliomas.
  • Determine the safety and tolerability of this regimen in these patients.


  • Determine the mechanism of action of lonafarnib in these patients.
  • Determine the pharmacodynamics and pharmacokinetics of this regimen in these patients.
  • Determine the activity of this regimen in these patients.
  • Determine the response to this regimen in patients who have measurable disease.

OUTLINE: This is a nonrandomized, multicenter, open-label, dose-escalation study of lonafarnib.

Patients receive oral temozolomide once daily on days 2-6 of course 1 and on days 1-5 of all subsequent courses. Patients also receive oral lonafarnib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of lonafarnib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 1 of 6 patients experience dose-limiting toxicity. An additional 3 patients may be treated at the highest dose level achieved.

Patients are followed every 8 weeks for 6 months and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed primary supratentorial glioma

    • Multifocal disease allowed
  • Recurrent disease after prior surgery and/or radiotherapy
  • Radiological evidence of increased and/or enhanced target lesion
  • Amenable to temozolomide therapy



  • Over 18

Performance status

  • ECOG 0-2 OR
  • WHO 0-2

Life expectancy

  • Not specified


  • Neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 10.0 g/dL


  • Alkaline phosphatase < 2.5 times upper limit of normal (ULN)
  • Transaminases < 2.5 times ULN
  • Bilirubin < 1.5 times ULN


  • Creatinine < 1.7 mg/dL


  • Cardiac function clinically normal
  • Normal 12-lead ECG
  • QTc ≤ 440 msec on ECG
  • No ischemic heart disease within the past 6 months


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study participation
  • No unstable systemic disease
  • No active uncontrolled infection
  • No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up
  • No other active or recurrent malignancy within the past 5 years except cone biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer


Biologic therapy

  • No concurrent anticancer biologic agents


  • At least 4 weeks since prior chemotherapy (6 weeks for temozolomide)
  • Prior adjuvant chemotherapy allowed
  • No more than 1 prior chemotherapy regimen for recurrent disease
  • No other concurrent chemotherapy

Endocrine therapy

  • Concurrent corticosteroids allowed provided treatment remains at a stable or decreasing dose for at least 2 weeks


  • See Disease Characteristics
  • No concurrent radiotherapy


  • See Disease Characteristics
  • At least 3 months since prior surgery for primary brain tumor


  • Concurrent anticonvulsants allowed
  • No other concurrent anticancer agents
  • No other concurrent investigational therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00083096

Centre de Lutte Contre le Cancer Georges-Francois Leclerc
Dijon, France, 21079
Centre Regional Rene Gauducheau
Nantes-Saint Herblain, France, 44805
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, CH-1011
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Study Chair: Mario Campone, MD Centre Regional Rene Gauducheau
  More Information

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00083096     History of Changes
Other Study ID Numbers: EORTC-16027-26023
Study First Received: May 14, 2004
Last Updated: February 9, 2015

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
recurrent adult brain tumor
adult mixed glioma
adult anaplastic astrocytoma
adult anaplastic oligodendroglioma
adult glioblastoma
adult pilocytic astrocytoma
adult anaplastic ependymoma
adult subependymoma
adult myxopapillary ependymoma
adult oligodendroglioma
adult giant cell glioblastoma
adult gliosarcoma
adult diffuse astrocytoma
adult subependymal giant cell astrocytoma
adult pineal gland astrocytoma

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on April 21, 2017